| Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates N Blagden, M De Matas, PT Gavan, P York Advanced drug delivery reviews 59 (7), 617-630, 2007 | 1758 | 2007 |
| Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients DJ Berry, CC Seaton, W Clegg, RW Harrington, SJ Coles, PN Horton, ... Crystal Growth and Design 8 (5), 1697-1712, 2008 | 407 | 2008 |
| Polymorphism in molecular crystals: stabilization of a metastable form by conformational mimicry RJ Davey, N Blagden, GD Potts, R Docherty Journal of the American Chemical Society 119 (7), 1767-1772, 1997 | 400 | 1997 |
| Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling HSM Ali, P York, AMA Ali, N Blagden Journal of controlled release 149 (2), 175-181, 2011 | 298 | 2011 |
| Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors HSM Ali, P York, N Blagden International journal of pharmaceutics 375 (1), 107-113, 2009 | 289 | 2009 |
| Polymorph selection: challenges for the future? N Blagden, RJ Davey Crystal growth & design 3 (6), 873-885, 2003 | 266 | 2003 |
| Crystal engineering-nucleation, the key step RJ Davey, K Allen, N Blagden, WI Cross, HF Lieberman, MJ Quayle, ... CrystEngComm 4 (47), 257-264, 2002 | 239 | 2002 |
| Crystal chemistry and solvent effects in polymorphic systems Sulfathiazole N Blagden, RJ Davey, HF Lieberman, L Williams, R Payne, R Roberts, ... Journal of the Chemical Society, Faraday Transactions 94 (8), 1035-1044, 1998 | 218 | 1998 |
| Current directions in co-crystal growth N Blagden, DJ Berry, A Parkin, H Javed, A Ibrahim, PT Gavan, ... New Journal of Chemistry 32 (10), 1659-1672, 2008 | 194 | 2008 |
| Crystal polymorphism as a probe for molecular self-assembly during nucleation from solutions: the case of 2, 6-dihydroxybenzoic acid RJ Davey, N Blagden, S Righini, H Alison, MJ Quayle, S Fuller Crystal Growth & Design 1 (1), 59-65, 2001 | 179 | 2001 |
| Nucleation control in solution mediated polymorphic phase transformations: The case of 2, 6-dihydroxybenzoic acid RJ Davey, N Blagden, S Righini, H Alison, ES Ferrari The Journal of Physical Chemistry B 106 (8), 1954-1959, 2002 | 135 | 2002 |
| Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole N Blagden, RJ Davey, R Rowe, R Roberts International journal of pharmaceutics 172 (1), 169-177, 1998 | 125 | 1998 |
| Pharmaceutical co-crystals–are we there yet? N Blagden, SJ Coles, DJ Berry CrystEngComm 16 (26), 5753-5761, 2014 | 116 | 2014 |
| A whole output strategy for polymorph screening: Combining crystal structure prediction, graph set analysis, and targeted crystallization experiments in the case of diflunisal WI Cross, N Blagden, RJ Davey, RG Pritchard, MA Neumann, RJ Roberts, ... Crystal growth & design 3 (2), 151-158, 2003 | 105 | 2003 |
| Controlling the formation of benzoic acid: isonicotinamide molecular complexes CC Seaton, A Parkin, CC Wilson, N Blagden Crystal Growth and Design 9 (1), 47-56, 2008 | 104 | 2008 |
| Polymorphism in benzamide WIF David, K Shankland, CR Pulham, N Blagden, RJ Davey, M Song Angewandte Chemie International Edition 44 (43), 7032-7035, 2005 | 88 | 2005 |
| Crystal Structure Prediction of Diastereomeric Salts: A Step toward Rationalization of Racemate Resolution. N Blagden, M Song, RJ Davey, L Seton | 69 | 2005 |
| Artificial neural networks modelling the prednisolone nanoprecipitation in microfluidic reactors HSM Ali, N Blagden, P York, A Amani, T Brook European Journal of Pharmaceutical Sciences 37 (3), 514-522, 2009 | 67 | 2009 |
| Solubility of budesonide, hydrocortisone, and prednisolone in ethanol+ water mixtures at 298.2 K HSM Ali, P York, N Blagden, S Soltanpour, WE Acree Jr, A Jouyban Journal of Chemical & Engineering Data 55 (1), 578-582, 2009 | 65 | 2009 |
| Polymorphs take shape N Blagden, R Davey Chemistry in Britain 35 (3), 44-45, 1999 | 64 | 1999 |
